Summary by Futu AI
Christopher Gibson, CEO of Recursion Pharmaceuticals, has engaged in a stock purchase transaction for the company's shares. On August 30, 2024, Gibson acquired 5,000 shares of Recursion Pharmaceuticals' Class A Common Stock at a price of $2.48 per share. Following this transaction, Gibson's direct holdings in the company increased to a total of 762,656 shares. The transaction is currently reported as in progress.